Synopsis
The WHO has acknowledged India's commendable leadership in pharmacopoeial standard-setting during the 15th IMWP, emphasizing the importance of regulatory harmonisation for global health.Key Takeaways
- India's leadership in pharmacopoeial standards is recognized.
- Regulatory harmonisation is crucial for patient safety.
- IMWP fosters international collaboration in pharmacopoeial science.
- IPC showcases advancements in pharmaceutical standards.
- Global partnerships are key to enhancing quality standards.
New Delhi, Feb 5 (NationPress) The commendable leadership of India in the domain of pharmacopoeial standard-setting was acknowledged by Dr. Roderico H. Ofrin, the WHO Representative to India, on Wednesday.
Dr. Ofrin emphasized the critical need for regulatory harmonisation to safeguard patient safety and promote public health.
This statement was made during his keynote address at the 15th International Meeting of World Pharmacopoeias (IMWP), organized by the Indian Pharmacopoeia Commission (IPC) in collaboration with the Ministry of Health and Family Welfare.
The three-day event, which runs until February 7, is being held in the national capital in partnership with the World Health Organization (WHO). Union Minister of State for Health and Family Welfare, Anupriya Patel, remarked, 'India is dedicated to global pharmaceutical standardization and regulatory convergence.'
Patel also pointed out India’s significant role as the 'Pharmacy of the World' and underlined the necessity of ensuring the global availability of high-quality medicines.
The IMWP is a crucial platform to enhance international collaboration in pharmacopoeial science and regulatory harmonisation, according to the Minister of State.
Additionally, the Union Minister unveiled the IPC Newsletter 2024 and a special video presentation that showcases the advancements made by India in pharmacopoeial science, highlighting the Commission's efforts to maintain high-quality pharmaceutical standards.
Meanwhile, Punya Salila Srivastava, Secretary of the Ministry of Health and Family Welfare, emphasized the importance of global partnerships in enhancing pharmaceutical quality standards.
Srivastava reiterated India’s commitment to aligning its regulatory frameworks with international best practices to ensure the worldwide availability of safe and effective medications.
The 15th IMWP will address critical focus areas, including emerging issues in impurity assessment (Q3) and the implications of ICH Q6 guidelines on pharmacopoeial monograph specifications.
Experts are also expected to discuss enhancing collaboration among global pharmacopeias and regulatory authorities, with updates from the Pharmacopoeial Discussion Group (PDG), as well as promoting environmental sustainability in pharmacopoeial practices and pharmaceutical manufacturing standards.
The discussions during the IMWP will reinforce the essential role of pharmacopeias in ensuring the quality, safety, and efficacy of medicines. The outcomes of this meeting will guide future collaborations in standard-setting and regulatory harmonisation.
The deliberations over these three days will pave the way for further strengthening global pharmacopoeial cooperation and enhancing pharmaceutical quality assurance.
